OrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into neuro vascular intervention and structural heart disease. As of June 30, 2024, OrbusNeich has more than 230 granted patents and published patent applications worldwide. Its in-house R&D team has more than two decades of product development experience and has developed world-leading proprietary technologies, including its Scoreflex NC product, the world’s smallest profile non-compliant scoring balloon; its proprietary “drug plus antibody” COMBO dual therapy stent; and its JADE non-compliant peripheral balloon, the first and only non-compliant over-the-wire PTA balloon approved by the FDA that is compatible with all guidewire systems in the U.S. OrbusNeich is listed on the Main Board of The Stock Exchange of Hong Kong Limited (“HKEX”), under the stock code 6929. For more information and news, visit http://www.orbusneich.com/. (Last updated on 30 August 2024)
$200M sweet spot round size
2000
$200M
from 2 investors over 1 rounds
OrbusNeich Medical Company Ltd. raised $200M on September 30, 2021
Investors: Shenzhen Capital Group and + 4 Other investors